BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 29881975)

  • 1. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stretch-activated two-pore-domain (K
    Schmidt C; Wiedmann F; Kallenberger SM; Ratte A; Schulte JS; Scholz B; Müller FU; Voigt N; Zafeiriou MP; Ehrlich JR; Tochtermann U; Veres G; Ruhparwar A; Karck M; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2017 Nov; 130(Pt B):233-243. PubMed ID: 28526353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
    Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
    J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of two-pore K
    Chai S; Wan X; Nassal DM; Liu H; Moravec CS; Ramirez-Navarro A; Deschênes I
    Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1144-H1153. PubMed ID: 28341634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Pore-Domain Potassium (K
    Wiedmann F; Frey N; Schmidt C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The two-pore domain potassium channel, TWIK-1, has a role in the regulation of heart rate and atrial size.
    Christensen AH; Chatelain FC; Huttner IG; Olesen MS; Soka M; Feliciangeli S; Horvat C; Santiago CF; Vandenberg JI; Schmitt N; Olesen SP; Lesage F; Fatkin D
    J Mol Cell Cardiol; 2016 Aug; 97():24-35. PubMed ID: 27103460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
    Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
    J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREK-1 (K
    Lugenbiel P; Wenz F; Syren P; Geschwill P; Govorov K; Seyler C; Frank D; Schweizer PA; Franke J; Weis T; Bruehl C; Schmack B; Ruhparwar A; Karck M; Frey N; Katus HA; Thomas D
    Basic Res Cardiol; 2017 Jan; 112(1):8. PubMed ID: 28005193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
    Skarsfeldt MA; Jepps TA; Bomholtz SH; Abildgaard L; Sørensen US; Gregers E; Svendsen JH; Diness JG; Grunnet M; Schmitt N; Olesen SP; Bentzen BH
    Pflugers Arch; 2016 Apr; 468(4):643-54. PubMed ID: 26729267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Dtsch Med Wochenschr; 2012 Aug; 137(33):1654-8. PubMed ID: 22875694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
    Gierten J; Ficker E; Bloehs R; Schlömer K; Kathöfer S; Scholz E; Zitron E; Kiesecker C; Bauer A; Becker R; Katus HA; Karle CA; Thomas D
    Br J Pharmacol; 2008 Aug; 154(8):1680-90. PubMed ID: 18516069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes.
    Limberg SH; Netter MF; Rolfes C; Rinné S; Schlichthörl G; Zuzarte M; Vassiliou T; Moosdorf R; Wulf H; Daut J; Sachse FB; Decher N
    Cell Physiol Biochem; 2011; 28(4):613-24. PubMed ID: 22178873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.